Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2013-06-30
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators believe that this study is of importance of several aspects:
1. It evaluates a new mode of bladder instillation that may bypass the drawbacks of the current instillation mode.
2. If proved effective this mode of treatment might save the need of TURBT performance and serve as a new mode of tumor ablation.
3. Even if proved partially effective this mode of treatment will diminish tumors size or number thus enable a more limited TURBT procedure.
4. This mode of treatment will enable immediate medical attendance to the patient's tumor recurrence without the waiting period (resulting from queues in the medical centers) for TURBT, which might improve the patient's prognostic outcome.
5. If this experimental treatment will prove to have a better ablative effect, this could be translated to a better prophylactic effect of tumor recurrence.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)
NCT01799499
Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients
NCT02307487
Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients
NCT02891460
Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer
NCT01648010
Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients
NCT06696794
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
TheraCoat core technology is based on a reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder.
Prior to instillation, the TC-3 hydrogel, in a liquid state, is mixed with MMC.TC-3 mixed with MMC is instilled to the bladder by a catheter. Following gel insertion to the bladder, the gel solidifies and forms a drug reservoir inside the bladder. Upon contact with urine the gel dissolves and is cleared out from the bladder.
Intravesical MMC instillation using TheraCoat gel is expected to increase treatment efficiency due to prolongation of treatment duration and consequently improving bladder exposure to MMC.
Treatment Protocol - Immediately following baseline cystoscopy and tumor diagnosis and patient undergoes 6 weekly instillations followed by 2-4 weeks healing period.
1st Follow-Up Visit (Pre-Scheduled TURBT Visit): The patient will undergo a second Cystoscopy to compare to the Baseline status and after that a follow-up period: 3,6,9,12 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
40 mg MMC gel
Device: TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 60 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter.
Other Name: MMC Gel
40 mg MMC gel
A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder.
Standard of care MMC mixed with water
40 mg MMC mixed with 40cc water. Six weekly intravesical instillations of 40 mg of MMC mixed with 40 cc of water will be instilled using catheter
Standard of care MMC mixed with water
Standard of care 40mg MMC mixed with water
80 mg MMC gel
Device: TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 60 cc of TC-3 gel mixed with 80 mg MMC will be instilled using catheter.
Other Name: MMC Gel
80 mg MMC gel
A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
40 mg MMC gel
A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder.
Standard of care MMC mixed with water
Standard of care 40mg MMC mixed with water
80 mg MMC gel
A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient has signed Informed Consent Form and is willing and able to abide by the protocol.
3. Naïve or recurrent low grade (LG) NMIBC tumor
4. Recurrent patients - Single or multiple tumors
5. Naive patients - 2 tumors or above
6. No prior history of HG and/or T1 in the past 5 years.
7. No prior history of Tis
8. At least one Tumor ≥ 1 mm as evaluated visually by the investigator.
9. Largest tumor diameter ≤ 30 mm as evaluated visually by the investigator
10. Cystoscopic appearance of papillary Low grade tumor
11. No active urinary tract infection as confirmed by urine culture
12. If the patient is a female of childbearing potential , she is using two acceptable \& effective methods of contraception , until 6 months post treatment
13. If the patient is a male he should use a condom during intercourse, for at least 48 hours post each instillation
14. If the patient is a male that has a partner that is a female of childbearing potential, he should be advised to use two acceptable \& effective methods of contraception until 6 months post treatment.
Exclusion Criteria
2. "High Grade" urine cytology which is conclusive for HG.
3. "High Grade" tumor results in cold cup biopsy.
4. Tumor located in prostatic urethra.
5. Previous systemic chemotherapy in the last 2 years or pelvic radiotherapy.
6. Pregnant or breastfeeding patient.
7. Previous treatment with BCG within the last 12 months.
8. The patient did not have at least 3 months cystoscopically confirmed tumor-free interval between the last TURBT to current tumor recurrence.
9. Treatment with full course of intravesical chemotherapy within the 3 last months.
10. The patient has/had any bladder tumor with histology other than TCC.
11. Known contraindication or hypersensitivity to MMC or gel.
12. The patient has a known history of upper urinary tract urothelial carcinoma, or Renal Cell carcinoma or other renal cancer.
13. The patient has a known urinary retention which, according to the investigator's opinion, might lead to avoid patient receiving the treatment.
14. The patient has a bleeding disorder or a screening platelet count \<50X109/L.
15. The patient has screening hemoglobin \<10 mg/dL.
16. The patient has a condition or a concurrent severe and/or uncontrolled medical or psychiatric disease (e.g. uncontrolled diabetes, compensated congestive heart failure (NYHA III and over), myocardial infarction within 6 months of study, unstable or uncontrolled hypertension or an active uncontrolled infection), which could compromise participation, compliance with scheduled visits and/or completion.
17. The patient participated in an investigational interventional study within the past 90 days.
18. The patient has documented sever vesico-ureteral reflux or an indwelling ureteral stent.
19. The patient has the tumor in the bladder diverticulum.
20. The patient participated in a prior TheraCoat's trial with MMC and TC-3
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UroGen Pharma Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fred Witjes, Prof
Role: PRINCIPAL_INVESTIGATOR
Radboud University Nijmegen Medical Centre, Department of Urology Geert Grooteplein South 10 (659), Nijmegen
Stenzl, Prof.
Role: PRINCIPAL_INVESTIGATOR
Tübingen Universitätsklinik für Urologie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Carmel Medical Center of Haifa, Department of Urology
Haifa, , Israel
Rambam Health Care Campus
Haifa, , Israel
Wolfson Medical Center of Holon, Department of Urology
Holon, , Israel
Meir medical center
Kfar Saba, , Israel
Galil Maaravi Medical Center of Nahariya, Department of Urology
Nahariya, , Israel
Rabin Medical Center of Petah Tikva, Department of Urology
Petach Tikvah, , Israel
Ziv Medical Center
Safed, , Israel
Vita Salute University, San Raffaele Hospital of Milan, Department of Urology
Milan, , Italy
S. Andrea Hospital of Rome, Department of Urology
Rome, , Italy
Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona
Salerno, , Italy
Fundacio Puigvert
Barcelona, , Spain
Hospital Universitario Infanta Sofìa of Madrid, Department of Urology
Madrid, , Spain
Hôpital HUG of Geneva, Department of Urology
Geneva, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TAS-4M-CS-0002-0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.